2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 min sittenAnyone who sees the similarities here?
·7 t sittenAs new to the stock environment, I don't have much experience, but I've never had more faith in a company like circio. I have bought at bad times and hoped that it would go up. Then I have seen it being attacked by short attacks and regretted everything. But I have read up on circio's development and research and have never felt myself in such safe hands before. This is a long investment based on hope for the company.
·7 t sittenPodcast for the weekend🙋🏻♂️ https://open.spotify.com/podcast-chapter/0331nHRexQwTOmqTWxcfEQ?si=ehcXBC_0R02bYgd2aB_hlw
·8 t sitten · MuokattuSome thoughts from me on a Saturday :) Especially this thing with the transition to more advanced preclinical models together with the cash… If they manage the transition, then my friends on Shareville, we'll be making money soon. Going from "survival" to sitting on a cash pile of several hundred million (and potentially almost a billion after redemption) is, I believe, like swapping a bicycle for a supersonic jet for Thomas Hanssen and his team. Here's what I, as a happy amateur, believe about how the new cash makes the "dream team" more dangerous for competitors and more attractive to Big Pharma: 1. From "Lamp" to "Medicine" (Reporter vs. Therapeutic) So far, the lab has primarily used reporter genes (e.g., luciferase). These are genes that "light up" to show that the technology works and how much RNA is produced. It's like testing an engine by just seeing if it can spin. What the money does: Now they can buy and develop the actual therapeutic "loads" (cargo). This is expensive. Designing and optimizing the specific sequences for, e.g., a heart disease or an eye disease requires massive computational power and specialized reagents. Disease models: Instead of just testing in healthy cells, they can now finance advanced disease models in mice and later primates. This is where you prove that circVec doesn't just "light up," but actually cures. 2. The Ingenuity in DNA -> circRNA (AAV & LNP) The approach is ingenious as I understand it. Most others talk about synthetic RNA that is injected (which breaks down quickly). Circio does the opposite: DNA as a factory blueprint: They deliver a DNA instruction (via AAV virus or LNP lipid nanoparticles). The cell as a factory: Inside the patient's cell, the DNA instruction begins to produce circular RNA (circVec). Because it is circular, the cell's cleaning patrols (exonucleases) don't "find" the ends of the strand, and it cannot be broken down. Why the cash is needed here and the salvation for us small investors on Shareville: Optimizing the "promoters" (the switches that determine when and where the DNA should start producing RNA) is an extremely iterative process. With money, Hanssen can run hundreds of experiments in parallel instead of ten at a time. This cuts years off development time. 3. Thomas Hanssen: "The Godfather of human circRNA" Having Thomas Hanssen as CTO is Circio's greatest intangible asset. He was involved in discovering circular RNA in humans together with Erik! Attracting talent: With a well-filled cash reserve, Circio can now recruit the absolute top researchers from all over the world. In biotech, talent follows the money and the most exciting technology. IP protection: Building a "patent wall" around their therapeutic candidates is extremely expensive. Now they can lock in every small detail of their "dream team's" discoveries so that no one can copy them once they reach the market. 4. From Feasibility to Fast-Track Previously, they had to wait for a partner (like their "Top 5 Pharma" collaboration) to pay for the tests. Now they own the pace, I believe: They can drive their own programs (e.g., in heart/eye) much longer before licensing them out. The more data they have in a therapeutic model, the more billions the price tag will be for an agreement. In short: The money allows Thomas Hanssen to stop worrying about buying pipettes and instead focus on proving that his life's work – circular RNA – is the new gold standard for modern medicine. Greetings from supersonicjohan who has read and watched EVERYTHING I could get my hands on about the subject in recent weeks, I believe. Thanks to Youtube (Erik Wiklund) tekinvestor and all experts on Shareville!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 min sittenAnyone who sees the similarities here?
- ·7 t sittenAs new to the stock environment, I don't have much experience, but I've never had more faith in a company like circio. I have bought at bad times and hoped that it would go up. Then I have seen it being attacked by short attacks and regretted everything. But I have read up on circio's development and research and have never felt myself in such safe hands before. This is a long investment based on hope for the company.
- ·7 t sittenPodcast for the weekend🙋🏻♂️ https://open.spotify.com/podcast-chapter/0331nHRexQwTOmqTWxcfEQ?si=ehcXBC_0R02bYgd2aB_hlw
- ·8 t sitten · MuokattuSome thoughts from me on a Saturday :) Especially this thing with the transition to more advanced preclinical models together with the cash… If they manage the transition, then my friends on Shareville, we'll be making money soon. Going from "survival" to sitting on a cash pile of several hundred million (and potentially almost a billion after redemption) is, I believe, like swapping a bicycle for a supersonic jet for Thomas Hanssen and his team. Here's what I, as a happy amateur, believe about how the new cash makes the "dream team" more dangerous for competitors and more attractive to Big Pharma: 1. From "Lamp" to "Medicine" (Reporter vs. Therapeutic) So far, the lab has primarily used reporter genes (e.g., luciferase). These are genes that "light up" to show that the technology works and how much RNA is produced. It's like testing an engine by just seeing if it can spin. What the money does: Now they can buy and develop the actual therapeutic "loads" (cargo). This is expensive. Designing and optimizing the specific sequences for, e.g., a heart disease or an eye disease requires massive computational power and specialized reagents. Disease models: Instead of just testing in healthy cells, they can now finance advanced disease models in mice and later primates. This is where you prove that circVec doesn't just "light up," but actually cures. 2. The Ingenuity in DNA -> circRNA (AAV & LNP) The approach is ingenious as I understand it. Most others talk about synthetic RNA that is injected (which breaks down quickly). Circio does the opposite: DNA as a factory blueprint: They deliver a DNA instruction (via AAV virus or LNP lipid nanoparticles). The cell as a factory: Inside the patient's cell, the DNA instruction begins to produce circular RNA (circVec). Because it is circular, the cell's cleaning patrols (exonucleases) don't "find" the ends of the strand, and it cannot be broken down. Why the cash is needed here and the salvation for us small investors on Shareville: Optimizing the "promoters" (the switches that determine when and where the DNA should start producing RNA) is an extremely iterative process. With money, Hanssen can run hundreds of experiments in parallel instead of ten at a time. This cuts years off development time. 3. Thomas Hanssen: "The Godfather of human circRNA" Having Thomas Hanssen as CTO is Circio's greatest intangible asset. He was involved in discovering circular RNA in humans together with Erik! Attracting talent: With a well-filled cash reserve, Circio can now recruit the absolute top researchers from all over the world. In biotech, talent follows the money and the most exciting technology. IP protection: Building a "patent wall" around their therapeutic candidates is extremely expensive. Now they can lock in every small detail of their "dream team's" discoveries so that no one can copy them once they reach the market. 4. From Feasibility to Fast-Track Previously, they had to wait for a partner (like their "Top 5 Pharma" collaboration) to pay for the tests. Now they own the pace, I believe: They can drive their own programs (e.g., in heart/eye) much longer before licensing them out. The more data they have in a therapeutic model, the more billions the price tag will be for an agreement. In short: The money allows Thomas Hanssen to stop worrying about buying pipettes and instead focus on proving that his life's work – circular RNA – is the new gold standard for modern medicine. Greetings from supersonicjohan who has read and watched EVERYTHING I could get my hands on about the subject in recent weeks, I believe. Thanks to Youtube (Erik Wiklund) tekinvestor and all experts on Shareville!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 min sittenAnyone who sees the similarities here?
- ·7 t sittenAs new to the stock environment, I don't have much experience, but I've never had more faith in a company like circio. I have bought at bad times and hoped that it would go up. Then I have seen it being attacked by short attacks and regretted everything. But I have read up on circio's development and research and have never felt myself in such safe hands before. This is a long investment based on hope for the company.
- ·7 t sittenPodcast for the weekend🙋🏻♂️ https://open.spotify.com/podcast-chapter/0331nHRexQwTOmqTWxcfEQ?si=ehcXBC_0R02bYgd2aB_hlw
- ·8 t sitten · MuokattuSome thoughts from me on a Saturday :) Especially this thing with the transition to more advanced preclinical models together with the cash… If they manage the transition, then my friends on Shareville, we'll be making money soon. Going from "survival" to sitting on a cash pile of several hundred million (and potentially almost a billion after redemption) is, I believe, like swapping a bicycle for a supersonic jet for Thomas Hanssen and his team. Here's what I, as a happy amateur, believe about how the new cash makes the "dream team" more dangerous for competitors and more attractive to Big Pharma: 1. From "Lamp" to "Medicine" (Reporter vs. Therapeutic) So far, the lab has primarily used reporter genes (e.g., luciferase). These are genes that "light up" to show that the technology works and how much RNA is produced. It's like testing an engine by just seeing if it can spin. What the money does: Now they can buy and develop the actual therapeutic "loads" (cargo). This is expensive. Designing and optimizing the specific sequences for, e.g., a heart disease or an eye disease requires massive computational power and specialized reagents. Disease models: Instead of just testing in healthy cells, they can now finance advanced disease models in mice and later primates. This is where you prove that circVec doesn't just "light up," but actually cures. 2. The Ingenuity in DNA -> circRNA (AAV & LNP) The approach is ingenious as I understand it. Most others talk about synthetic RNA that is injected (which breaks down quickly). Circio does the opposite: DNA as a factory blueprint: They deliver a DNA instruction (via AAV virus or LNP lipid nanoparticles). The cell as a factory: Inside the patient's cell, the DNA instruction begins to produce circular RNA (circVec). Because it is circular, the cell's cleaning patrols (exonucleases) don't "find" the ends of the strand, and it cannot be broken down. Why the cash is needed here and the salvation for us small investors on Shareville: Optimizing the "promoters" (the switches that determine when and where the DNA should start producing RNA) is an extremely iterative process. With money, Hanssen can run hundreds of experiments in parallel instead of ten at a time. This cuts years off development time. 3. Thomas Hanssen: "The Godfather of human circRNA" Having Thomas Hanssen as CTO is Circio's greatest intangible asset. He was involved in discovering circular RNA in humans together with Erik! Attracting talent: With a well-filled cash reserve, Circio can now recruit the absolute top researchers from all over the world. In biotech, talent follows the money and the most exciting technology. IP protection: Building a "patent wall" around their therapeutic candidates is extremely expensive. Now they can lock in every small detail of their "dream team's" discoveries so that no one can copy them once they reach the market. 4. From Feasibility to Fast-Track Previously, they had to wait for a partner (like their "Top 5 Pharma" collaboration) to pay for the tests. Now they own the pace, I believe: They can drive their own programs (e.g., in heart/eye) much longer before licensing them out. The more data they have in a therapeutic model, the more billions the price tag will be for an agreement. In short: The money allows Thomas Hanssen to stop worrying about buying pipettes and instead focus on proving that his life's work – circular RNA – is the new gold standard for modern medicine. Greetings from supersonicjohan who has read and watched EVERYTHING I could get my hands on about the subject in recent weeks, I believe. Thanks to Youtube (Erik Wiklund) tekinvestor and all experts on Shareville!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt